NASDAQ:GERN Geron (GERN) Stock Price, News & Analysis $1.64 -0.03 (-1.80%) Closing price 04:00 PM EasternExtended Trading$1.64 0.00 (-0.30%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Geron Stock (NASDAQ:GERN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Geron alerts:Sign Up Key Stats Today's Range$1.61▼$1.7350-Day Range$1.60▼$3.5752-Week Range$1.46▼$5.34Volume8.60 million shsAverage Volume11.36 million shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$5.68Consensus RatingModerate Buy Company OverviewGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Read More… Remove Ads Geron Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreGERN MarketRank™: Geron scored higher than 88% of companies evaluated by MarketBeat, and ranked 112th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingGeron has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageGeron has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Geron's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Geron are expected to grow in the coming year, from ($0.25) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 3.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Geron's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.97% of the float of Geron has been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Geron has recently decreased by 16.28%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. Sustainability and ESG1.3 / 5Environmental Score-2.76 Percentage of Shares Shorted9.97% of the float of Geron has been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Geron has recently decreased by 16.28%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment0.26 News SentimentGeron has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Geron this week, compared to 7 articles on an average week.Search Interest25 people have searched for GERN on MarketBeat in the last 30 days. This is an increase of 47% compared to the previous 30 days.MarketBeat Follows22 people have added Geron to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Geron insiders have bought more of their company's stock than they have sold. Specifically, they have bought $46,150.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of Geron is held by insiders.Percentage Held by Institutions73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Geron's insider trading history. Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Email Address GERN Stock News HeadlinesInsider Buying: Geron Co. (NASDAQ:GERN) CEO Acquires 12,500 Shares of StockMarch 4, 2025 | insidertrades.comGERN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMarch 14 at 4:00 PM | globenewswire.comElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...March 14, 2025 | American Hartford Gold (Ad)Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Geron Corporation (GERN)March 14 at 3:04 PM | globenewswire.comRosen Law Firm Urges Geron Corporation (NASDAQ: GERN) Stockholders to Contact the Firm for ...March 14 at 12:08 PM | gurufocus.comINVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Geron Corporation (GERN) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the FirmMarch 14 at 10:39 AM | globenewswire.comGERN INVESTOR ALERT: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMarch 14 at 6:30 AM | prnewswire.comGERN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead the Geron Class Action LawsuitMarch 13 at 5:23 PM | globenewswire.comSee More Headlines GERN Stock Analysis - Frequently Asked Questions How have GERN shares performed this year? Geron's stock was trading at $3.54 at the start of the year. Since then, GERN stock has decreased by 54.1% and is now trading at $1.6250. View the best growth stocks for 2025 here. How were Geron's earnings last quarter? Geron Co. (NASDAQ:GERN) released its earnings results on Wednesday, February, 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). The biopharmaceutical company earned $47.54 million during the quarter, compared to analyst estimates of $45.29 million. Geron had a negative trailing twelve-month return on equity of 67.53% and a negative net margin of 682.48%. Who are Geron's major shareholders? Geron's top institutional shareholders include Vanguard Group Inc. (5.55%), RA Capital Management L.P. (4.96%), Janus Henderson Group PLC (4.48%) and Adage Capital Partners GP L.L.C. (3.61%). Insiders that own company stock include Olivia Kyusuk Bloom, Scott Alan Samuels, John A Scarlett, Elizabeth G O'farrell, Faye Feller and Andrew J Grethlein. View institutional ownership trends. How do I buy shares of Geron? Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some other companies that Geron investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Novavax (NVAX), Advanced Micro Devices (AMD), Intel (INTC) and Bristol-Myers Squibb (BMY). Company Calendar Last Earnings2/26/2025Today3/14/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:GERN CIK886744 Webwww.geron.com Phone(650) 473-7700Fax650-473-7750Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$5.68 High Stock Price Target$10.00 Low Stock Price Target$2.00 Potential Upside/Downside+240.2%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,130,000.00 Net Margins-682.48% Pretax Margin-682.47% Return on Equity-67.53% Return on Assets-45.46% Debt Debt-to-Equity Ratio0.04 Current Ratio2.89 Quick Ratio2.74 Sales & Book Value Annual Sales$76.99 million Price / Sales13.81 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book3.63Miscellaneous Outstanding Shares636,904,000Free Float585,761,000Market Cap$1.06 billion OptionableOptionable Beta0.53 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:GERN) was last updated on 3/14/2025 by MarketBeat.com Staff From Our PartnersElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBITCOINYou're not going to believe this. There's a bizarre new way to make money from crypto... ...and it's not...Awesomely, LLC | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredElon’s desperate gambleWarning: "DOGE Collapse" Imminent After months of cost-cutting, controversy, and media buzz, DOGE is on the...Altimetry | SponsoredTrump’s new tariffs could break China’s grip on manufacturingLooming trade wars have China scrambling… Over 90% of global corporate executives said they are shutting do...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.